Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cynata Therapeutics Limited ( (AU:CYP) ) just unveiled an update.
Cynata Therapeutics announced that the recent orphan-drug exclusivity granted to Ryoncil® by the US FDA will not hinder the approval pathway for its own product, CYP-001. CYP-001, which is under investigation for treating high-risk aGvHD in adults, differs from Ryoncil® in its active agent and indication, thus not falling under the same exclusivity constraints. This development supports Cynata’s strategic positioning in the biotechnology industry, as it continues to leverage its robust patent portfolio and proprietary technology to advance its therapeutic candidates.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform, which utilizes induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) at a commercial scale. Cynata is advancing various clinical trials for conditions such as acute graft versus host disease (GvHD), diabetic foot ulcers, kidney transplantation, and osteoarthritis.
Average Trading Volume: 191,293
Technical Sentiment Signal: Sell
Current Market Cap: A$42.93M
Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.